Mergers & Acquisitions


Current filters:


Popular Filters

701 to 725 of 909 results

Empty pipelines drive deal valuations in pharmaceuticals sector, say IMAP


A drought of domestic growth opportunities and new products is inflating valuations for R&D companies…

BiotechnologyMergers & AcquisitionsPharmaceuticalResearch

Life sciences M&A activity heats Up in April, says Burrill & Co


April proved to be a big month for M&A activity in the life sciences as companies announced more than…

BiotechnologyFinancialMergers & AcquisitionsPharmaceutical

Valeant Pharma to acquire assets from University Medical; posts 1st-qtr loss


Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says it has agreed to…

FinancialMergers & AcquisitionsPharmaceuticalUniversity Medical PharmaValeant Pharmaceuticals

Novartis to buy US generic derma company Fougera for over $1.5 billion


Further expanding its generic drug foot print, Swiss drug giant Novartis (NOVN: VX) is adding to its…

DermatologicalsFougera PharmaceuticalsGenericsMergers & AcquisitionsNovartisPharmaceuticalSandoz

Gen-Probe agrees $3.7 billion acquisition by Hologic


USA-based Hologic (Nasdaq: HOLX) said it has reached an agreement to acquire Gen-Probe (Nasdaq: ASDAQ)…

Gen-ProbeHologicMergers & AcquisitionsPharmaceutical

Haemonetics to buy Pall Corp blood collection and processing lines for $550 million; and Hemerus Medical


USA-based Pall Corp (NYSE: PLL) has entered into an agreement to sell certain assets of its blood collection,…

HaemoneticsHemerus MedicalMergers & AcquisitionsPall CorpPharmaceutical

Jazz Pharma to acquire EUSA Pharma for up to $700 million


US drugmaker Jazz Pharmaceuticals (Nasdaq: JAZZ) said last week that it has signed a definitive accord…

EUSA PharmaJazz PharmaceuticalsMergers & AcquisitionsPharmaceutical

Global generic drug markets will grow to $221 billion by 2016; Espicom


The economic recession has been a double-edged sword for the international generic drugs business. Driven…

GenericsGlobalMarkets & MarketingMergers & AcquisitionsPricing

Amylin operating loss leaps to over $30 million


US biotech firm Amylin Pharmaceuticals (Nasdaq AMLN): reported financial results for the quarter ended…

AmylinBiotechnologyFinancialMergers & Acquisitions

Fitch puts Watson on rating watch Negative on planned acquisition of Actavis


US generics drugmaker Watson Pharmaceuticals (NYSE: WPI) has seen its rating downgraded by Fitch Ratings,…

ActavisFinancialGenericsMergers & AcquisitionsNorth AmericaWatson Pharmaceuticals

Watson Pharma confirms buy of generic group Actavis for 4.25 billion euros


As has been widely rumoured over this week, Watson Pharmaceuticals (NYSE: WPI) has confirmed a definitive…

ActavisGenericsMergers & AcquisitionsWatson Pharmaceuticals

Amgen acquires Turkish drugmaker Mustafa Nevzat for $700 million


Global biotech giant Amgen (Nasdaq: AMGN) has reached agreement to acquire 95.6% of Mustafa Nevzat Pharmaceuticals…

AmgenBiotechnologyMergers & AcquisitionsMustafa Nevzat PharmaPharmaceutical

Biota and Nabi announce proposed merger


Australian firm Biota Holdings (ASX: BTA) and USA-based Nabi Biopharmaceuticals (Nasdaq: NABI) yesterday…

Biota HoldingsBiota PharmaceuticalsBiotechnologyMergers & AcquisitionsNabi BiopharmaceuticalsPharmaceutical

Pfizer sells Nutrition business to Nestle for $11.85 billion


Swiss food giant Nestle has won the battle to acquire the Nutrition business of global drugs behemoth…

Mergers & AcquisitionsNestlePfizerPharmaceutical

EU Commission OKs J&J's buy of Synthes, but with conditions


The European Commission last week cleared under the EU Merger Regulation the proposed $21.3 billion acquisition…

Johnson & JohnsonMergers & AcquisitionsPharmaceuticalSynthes

Human Genome rejects unsolicited takeover bid from GlaxoSmithKline


US drugmaker Human Genome Sciences (Nasdaq: HGSI) revealed yesterday that it has rejected an unsolicited…

BiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

Roche will not extend its tender offer for Illumina


In view of the apparent re-election of the incumbent directors of Illumina (Nasdaq: ILMN), a leading…

BiotechnologyIlluminaMergers & AcquisitionsPharmaceuticalRoche

701 to 725 of 909 results

Company Spotlight



Back to top